UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

This summary covers recent health events including investment in German firm Gerresheimer, updates on the U.S. Medicare drug ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion ...

While the focus of this research is largely on illegal drugs and markets, we also monitor trends in the use of pharmaceutical stimulants, such as ADHD drugs, without a prescription. This year ...

Another jury in the same courthouse handed a verdict last month to a separate Zantac manufacturer, GlaxoSmithKline. On May 23, an Illinois jury sided with both drug manufacturers in the first ...